share_log

Morgan Stanley Initiates Coverage On Mural Oncology With Overweight Rating, Announces Price Target of $13

Benzinga ·  Apr 4 18:39

Morgan Stanley analyst Judah Frommer initiates coverage on Mural Oncology (NASDAQ:MURA) with a Overweight rating and announces Price Target of $13.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment